In their study, Li and colleagues reported that SIRT5 has the ability to counteract metabolic abnormalities and apoptosis resistance in glioma cells harboring IDH1 mutation, resulting in impaired cell growth both in vitro and in vivo [166]. The gene discussed is IDH1; the disease is central nervous system cancer.